Limits...
Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy.

Klein FH, Brenner FM, Sato MS, Robert FM, Helmer KA - An Bras Dermatol (2014 Nov-Dec)

Bottom Line: Observed adverse effects were masticatory fatigue, smile limitation, and smile asymmetry.Smile limitation had a higher incidence compared to that reported in the literature and may result from risorius muscle blockage caused by toxin dissemination.Despite its side effects, 80% of the patients would like to repeat the treatment.

View Article: PubMed Central - PubMed

Affiliation: Private practice particular - Criciúma (SC), Brazil, Criciúma, SC, Brazil.

ABSTRACT

Background: Masseter hypertrophy has been treated with botulinum toxin injections because of esthetic complaints especially in Asians.

Objectives: The goal of the present study was to evaluate the efficacy of abobotulin toxin use in masseter hipertrophy treatment in Brazilians.

Methods: Ten Brazilian female patients with masseter hypertrophy were subjected to injections of 90U of abobotulinum toxin A applied on each side respecting the safety zone stabilished in literature and were followed up for 24 weeks.

Results: When analyzing the coefficients between measures of middle and lower third of the face obtained from standardized photographs, an increase was observed, with statistical significance at 2 weeks (p=0.005) and 12 weeks (p=0.001). The progression of lower third reduction was 3.94%, 5.26%, 11.99%, and 5.47% (2, 4, 12, and 24 weeks respectively). All patients showed improvement in bruxism after treatment. Observed adverse effects were masticatory fatigue, smile limitation, and smile asymmetry.

Conclusion: The use of abobotulinum toxin A for masseter hypertrophy is effective in Brazilians and reached its maximum effect of facial thinning at 12 weeks. Smile limitation had a higher incidence compared to that reported in the literature and may result from risorius muscle blockage caused by toxin dissemination. Despite its side effects, 80% of the patients would like to repeat the treatment.

Show MeSH

Related in: MedlinePlus

Examples of results – images obtained before treatment on the left(A) and after 3 months on the right (B)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4230655&req=5

f04: Examples of results – images obtained before treatment on the left(A) and after 3 months on the right (B)

Mentions: The efficacy of the use to botulinum toxin type A in reducing lower facial volume hasbeen proven by several imaging methods and by photographic analyses.2,7,9,11,12,15,20,24 Data obtained in the present study are in agreement withthose of the literature. According to the analysis of the coefficient between measuresfor middle and lower thirds of the face, which were taken using photographs obtained atstandardized distance and positioning, this technique showed to be effective inthickening the face at 2 weeks (p=0.000) and at 12 weeks (p=0.000) in photographs withthe muscles relaxed and at the same time points in photographs with the teeth ground(p=0.005 and p=0.001 respectively) (Figure 3)


Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy.

Klein FH, Brenner FM, Sato MS, Robert FM, Helmer KA - An Bras Dermatol (2014 Nov-Dec)

Examples of results – images obtained before treatment on the left(A) and after 3 months on the right (B)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4230655&req=5

f04: Examples of results – images obtained before treatment on the left(A) and after 3 months on the right (B)
Mentions: The efficacy of the use to botulinum toxin type A in reducing lower facial volume hasbeen proven by several imaging methods and by photographic analyses.2,7,9,11,12,15,20,24 Data obtained in the present study are in agreement withthose of the literature. According to the analysis of the coefficient between measuresfor middle and lower thirds of the face, which were taken using photographs obtained atstandardized distance and positioning, this technique showed to be effective inthickening the face at 2 weeks (p=0.000) and at 12 weeks (p=0.000) in photographs withthe muscles relaxed and at the same time points in photographs with the teeth ground(p=0.005 and p=0.001 respectively) (Figure 3)

Bottom Line: Observed adverse effects were masticatory fatigue, smile limitation, and smile asymmetry.Smile limitation had a higher incidence compared to that reported in the literature and may result from risorius muscle blockage caused by toxin dissemination.Despite its side effects, 80% of the patients would like to repeat the treatment.

View Article: PubMed Central - PubMed

Affiliation: Private practice particular - Criciúma (SC), Brazil, Criciúma, SC, Brazil.

ABSTRACT

Background: Masseter hypertrophy has been treated with botulinum toxin injections because of esthetic complaints especially in Asians.

Objectives: The goal of the present study was to evaluate the efficacy of abobotulin toxin use in masseter hipertrophy treatment in Brazilians.

Methods: Ten Brazilian female patients with masseter hypertrophy were subjected to injections of 90U of abobotulinum toxin A applied on each side respecting the safety zone stabilished in literature and were followed up for 24 weeks.

Results: When analyzing the coefficients between measures of middle and lower third of the face obtained from standardized photographs, an increase was observed, with statistical significance at 2 weeks (p=0.005) and 12 weeks (p=0.001). The progression of lower third reduction was 3.94%, 5.26%, 11.99%, and 5.47% (2, 4, 12, and 24 weeks respectively). All patients showed improvement in bruxism after treatment. Observed adverse effects were masticatory fatigue, smile limitation, and smile asymmetry.

Conclusion: The use of abobotulinum toxin A for masseter hypertrophy is effective in Brazilians and reached its maximum effect of facial thinning at 12 weeks. Smile limitation had a higher incidence compared to that reported in the literature and may result from risorius muscle blockage caused by toxin dissemination. Despite its side effects, 80% of the patients would like to repeat the treatment.

Show MeSH
Related in: MedlinePlus